Painchek Ltd (ASX: PCK) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Painchek Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Painchek Ltd (ASX: PCK)
Latest News

Healthcare Shares
Why did this ASX biotech stock explode 36% today?

Share Gainers
What the heck is going on with the PainChek (ASX:PCK) share price?

Healthcare Shares
The PainChek (ASX:PCK) share price is rising on its latest announcement

Healthcare Shares
Why the Painchek (ASX:PCK) share price is charging 13% higher

Share Gainers
Why Lake Resources, PainChek, Z Energy, & Zip shares are rising today

Share Market News
Why the Painchek (ASX:PCK) share price is edging higher today

Share Market News
Why the Painchek (ASX:PCK) share price lifted today
Share Fallers
PainChek (ASX:PCK) share price lower despite Ramsay (ASX:RHC) partnership
PCK ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Painchek Ltd
Painchek Ltd is engaged in the development and commercialization of mobile medical device applications, that automate intelligent pain assessment of individuals who are unable to communicate pain with carers. It operates in one segment namely sale of pain assessment solutions.
PCK Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
28 Nov 2023 | $0.04 | $0.00 | 0.00% | 839,777 | $0.04 | $0.04 | $0.04 |
27 Nov 2023 | $0.04 | $-0.01 | -23.26% | 3,018,367 | $0.04 | $0.04 | $0.04 |
24 Nov 2023 | $0.04 | $0.00 | 0.00% | 319,479 | $0.04 | $0.04 | $0.04 |
23 Nov 2023 | $0.04 | $0.00 | 0.00% | 1,631,399 | $0.04 | $0.04 | $0.04 |
22 Nov 2023 | $0.04 | $0.00 | 0.00% | 1,082,723 | $0.05 | $0.05 | $0.04 |
21 Nov 2023 | $0.04 | $0.00 | 0.00% | 1,223,701 | $0.05 | $0.05 | $0.04 |
20 Nov 2023 | $0.05 | $0.00 | 0.00% | 2,111,609 | $0.05 | $0.05 | $0.05 |
17 Nov 2023 | $0.05 | $0.00 | 0.00% | 445,249 | $0.05 | $0.05 | $0.04 |
16 Nov 2023 | $0.04 | $0.00 | 0.00% | 1,446,398 | $0.04 | $0.04 | $0.04 |
15 Nov 2023 | $0.04 | $0.00 | 0.00% | 509,915 | $0.04 | $0.04 | $0.04 |
14 Nov 2023 | $0.04 | $0.00 | 0.00% | 713,110 | $0.04 | $0.04 | $0.04 |
13 Nov 2023 | $0.04 | $0.00 | 0.00% | 1,590,536 | $0.04 | $0.04 | $0.04 |
10 Nov 2023 | $0.04 | $0.00 | 0.00% | 967,473 | $0.04 | $0.04 | $0.04 |
09 Nov 2023 | $0.04 | $0.00 | 0.00% | 3,228,051 | $0.04 | $0.04 | $0.04 |
08 Nov 2023 | $0.04 | $0.00 | 0.00% | 3,323,545 | $0.04 | $0.04 | $0.04 |
07 Nov 2023 | $0.04 | $0.00 | 0.00% | 484,046 | $0.04 | $0.04 | $0.04 |
06 Nov 2023 | $0.04 | $0.00 | 0.00% | 1,594,081 | $0.04 | $0.04 | $0.04 |
03 Nov 2023 | $0.04 | $0.00 | 0.00% | 397,091 | $0.04 | $0.04 | $0.04 |
02 Nov 2023 | $0.04 | $0.00 | 0.00% | 2,049,057 | $0.04 | $0.04 | $0.04 |
01 Nov 2023 | $0.04 | $0.00 | 0.00% | 576,412 | $0.04 | $0.05 | $0.04 |
31 Oct 2023 | $0.05 | $0.00 | 0.00% | 3,360,690 | $0.05 | $0.05 | $0.04 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
09 Nov 2023 | Adam Davey | Issued | 477,327 | $20,000 |
Director remuneration. Est. value, 477,327 Rights
|
09 Nov 2023 | Philip Daffas | Issued | 5,966,587 | $250,000 |
Director remuneration. Est. value, 19,404,907 Performance Rights
|
09 Nov 2023 | John Murray | Issued | 954,654 | $40,000 |
Director remuneration. Est. value, 954,654 Performance Rights
|
09 Nov 2023 | Ross Harricks | Issued | 477,327 | $20,000 |
Director remuneration. Est. value, 477,327 Performance Rights
|
09 Nov 2023 | Cynthia Payne | Issued | 477,327 | $20,000 |
Director remuneration. Est. value, 477,327 Performance Rights
|
27 Sep 2023 | Cynthia Payne | Buy | 675,676 | $20,000 |
Conversion of securities. Est. value
|
27 Sep 2023 | Cynthia Payne | Exercise | 675,676 | $20,000 |
Conversion of securities. Est. value
|
27 Sep 2023 | Ross Harricks | Buy | 675,676 | $20,000 |
Conversion of securities. Est. value
|
27 Sep 2023 | Ross Harricks | Exercise | 675,676 | $20,000 |
Conversion of securities. Est. value
|
27 Sep 2023 | John Murray | Buy | 1,351,351 | $40,000 |
Conversion of securities. Est. value, As per announcement on 04-10-2023
|
27 Sep 2023 | John Murray | Exercise | 1,351,351 | $40,000 |
Conversion of securities. Est. value
|
27 Sep 2023 | Adam Davey | Buy | 675,676 | $20,000 |
Conversion of securities. Est. value, As per announcement on 04-10-2023
|
27 Sep 2023 | Adam Davey | Exercise | 675,676 | $20,000 |
Conversion of securities. Est. value
|
13 Feb 2023 | Philip Daffas | Issued | 8,445,945 | $228,040 |
Issue of securities. Est., 13,438,320 Rights
|
13 Feb 2023 | John Murray | Issued | 1,351,351 | $36,486 |
Issue of securities. estd., 1,351,351 Rights
|
13 Feb 2023 | Cynthia Payne | Issued | 675,676 | $18,243 |
Issue of securities. Est. value, 675,676 Performance Rights
|
13 Feb 2023 | Adam Davey | Issued | 675,676 | $18,243 |
Issue of securities. 675,676 Performance Rights, ESTD.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Adam Stuart Davey | Non-Executive Director | Sep 2014 |
Mr Davey is a Director of Wealth Management at Canaccord Genuity Patersons Limited. Mr Davey has been involved in growing businesses in both the industrial and mining sector. Mr Davey's expertise spans over 25 years and includes capital raising (both private and public), mergers and acquisition, ASX listings, asset sales and purchases, transaction due diligence and director duties. This has been achieved through holding various roles within different organisations, including chairman, managing director, non-executive director, major shareholder and corporate adviser to the board. Mr Davey is a non-executive director of Ensurance Limited and the Agency Group Australia Ltd.
|
Mr Philip Daffas | Chief Executive OfficerManaging Director | Sep 2016 |
Mr Daffas is a global business leader and people manager with an international career spanning more than 25 years with leading blue-chip healthcare corporates and novel technology start-up companies. Philip has held senior global business leader positions in Europe, US and Australia. He has been instrumental in building businesses, growing market share and developing extensive high-level customer and industry relationships in each sector on a global basis. Philip's earlier experience was gained in Europe with market leaders such as IVAC infusion systems and Shiley cardiopulmonary products. He subsequently joined Boehringer Mannheim, initially in the UK managing their diagnostics business and subsequently was promoted to a Global Marketing role in the Diabetes Care business cased in Mannheim, Germany. In 1997 Philip joined Cochlear in the UK as the European Sales and Marketing Manager and subsequently was promoted in 2000 to the VP Global Marketing role based in Sydney, Australia Other roles in Australia have included General Manager with Roche Diagnostics, Managing Director at Bio-Rad Laboratories and CEO of Applied Physiology, an Australian software start up company in the intensive care monitoring sector.
|
Mr John Murray | Non-Executive ChairmanNon-Executive Director | Sep 2016 |
Mr Murray has 25 years experience in private equity and venture capital and was a co-founder and Managing Partner of Technology Venture Partners; one of the original and leading venture capital firms in Australia. Mr Murray is a past chairman of the Australian Venture Capital Association. Mr Murray has considerable experience as an investor and a non-executive director of high growth, technologybased companies. He possesses a broad understanding of global trends in technology and its impact on a variety of industries. He is a past Chairman of a private, residential aged care business in Australia. Mr Murray also brings 12 years experience in executive roles in corporate banking, accounting and IT services industries. Mr Murray has been on the Board of a number of successful technology rollouts and exits including online travel play Viator, which was acquired by TripAdvisor for approximately US$200 million in 2014. Mr Murray is a director of UK AIM listed company Seeing Machines Ltd.
|
Mr Ross Harricks | Non-Executive Director | Sep 2016 |
Mr Harricks has experience in the commercialisation of medical products which spans over forty years and over three continents. His experience includes the marketing and commercialising of the computed technology scanner (CT or CAT scanner) in Australia, where he headed up the EMI Electronics Group as General Manager. His remit included developing EMI's medical business in this region. In 1983, Mr Harricks joined the Nucleus Group as Group Marketing Executive, and later became President the two Nucleus Group subsidiaries in United States marketing medical equipment and scientific and engineering computing products. In 1989 in the US, Mr Harricks was the CEO of a venture capital-backed start-up company developing specialist scientific and medical lasers. In Australia Mr Harricks has been a director of ResMed Limited and cofounder of AtCor Medical where he completed an Australian initial public offering in 2005 leading the company until 2007. He was a director of VentraCor from 2005 to 2009. Mr Harricks works with Australian medical and technology companies assisting in commercialisation of their products into the US and EU markets. His unique expertise and experience includes strategic advising on the best path to early international market endorsement and adoption, and on providing hands-on help with implementation in the American and European markets.
|
Ms Cynthia Payne | Non-Executive Director | Mar 2022 |
Ms Payne brings 30 years executive leadership experience as well as board and operational experience in residential and home aged care services in Australia. That experience includes over 16 years as CEO for a large private aged care Provider in NSW and before that head of operation manager for a large Not for Profit with home care, residential and retirement living portfolios. She is the founder and Managing Director of Anchor Excellence, a consultancy firm in the aged care services industry in Australia that advises boards and management on operational and compliance best practices. Ms Payne is currently a board advisor to Total Constructions Pty Ltd, a former Director of the Heart Foundation and past Chair of Business Excellence Australia. She is a Certified Chair with The Board Advisory centre.
|
Ms Lisa Dadswell | Company Secretary | Dec 2022 |
-
|
Iain McAdam | Chief Financial Officer |
-
|
|
Lisa Dadswell | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
PETERS INVESTMENTS PTY LTD | 118,650,000 | 9.14% |
Hsbc Custody Nominees (Australia) Limited | 67,710,244 | 5.22% |
J&E CONSULTING PTY LTD | 38,003,125 | 2.93% |
DR KRESHNIK HOTI | 37,717,411 | 2.91% |
MR MUSTAFA ABDUL WAHED ATEE | 37,003,125 | 2.85% |
Bnp Paribas Noms Pty Ltd <Drp> | 29,143,853 | 2.25% |
MR PHILIP DAFFAS | 21,524,560 | 1.66% |
MR CRAIG ROBERT WILLIAMSON | 19,255,683 | 1.48% |
THORNBURY NOMINEES PTY LTD <THE STEVENS FAMILY S/F A/C> | 15,802,500 | 1.22% |
MR ALLAN GRAHAM JENZEN & MRS ELIZABETH JENZEN <AG & EJENZEN P/L NO2 SF A/C> | 14,141,873 | 1.09% |
G & G CHILCOTT PTY LTD <G & G CHILCOTT S/F A/C> | 13,927,169 | 1.07% |
NANJOP PTY LTD <THE MURRING FAMILY A/C> | 12,914,735 | 0.99% |
MR ROBERT ANTHONY HEALY i | 12,857,143 | 0.99% |
MS ELOISE KATHLEEN JENNINGS & MR ANDREW JOHN HOPKINS <JENNINGS HOPKINS DISCRET A/C> | 12,129,791 | 0.94% |
Citicorp Nominees Pty Limited | 11,675,234 | 0.90% |
CAPPER SUPERANNUATION PTY LTD <CAPPER SUPER FUND A/C> | 11,674,331 | 0.90% |
MR ROBERT ANTHONY HEALY | 11,000,000 | 0.85% |
FLUE HOLDINGS PTY LTD <BROMLEY SUPERANNUATION A/C> | 10,758,457 | 0.83% |
MR SHANNON JOHN GORMAN | 10,463,516 | 0.81% |
MR ADAM STUART DAVEY <SHENTON PARK INVESTMENT A/C> | 10,175,170 | 0.78% |